Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zoledronic Acid Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 10/20 | 1.00 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.96 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.96 |
| ▸ | CA12 | O43570 | 1/20 | 0.96 |
| ▸ | CA2 | P00918 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | MMP2 | P08253 | 1/20 | 0.96 |
| ▸ | MMP9 | P14780 | 1/20 | 0.96 |
| ▸ | MMP8 | P22894 | 1/20 | 0.96 |
| ▸ | MMP14 | P50281 | 1/20 | 0.96 |
| ▸ | CA9 | Q16790 | 1/20 | 0.96 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zoledronic Acid Anhydrous SCHEMBL1586366 | 1.00 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160460 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL22534391 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3156249 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3180138 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL515095 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160625 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL435847 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160616 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL14603422 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 47848 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146260-A1 | Transduction of gammadelta T cells with pseudotyped retroviral vectors | Miltenyi Biotec B.V. & Co. KG (DE) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-118873499-B | Preparation and application of multifunctional nano preparation for activating tumor in-situ vaccine to generate immune response | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122075712-A | Antitumor composition of engineering bacteria and bisphosphonate compounds for expressing hemolysin and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081252-A | PDHC mutant, immunogenic fragment and application | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137780-A1 | MATERIALS AND METHODS FOR IMPROVED EXPANSION AND USES OF IMMUNE CELLS | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-0758241-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | Novartis AG (CH) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030421-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | claimed |
| EP-0573604-B1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1995-03-15 | — | — | EP | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| US-4939130-A | Substituted alkanediphosphonic acids and pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | claimed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | claimed |